WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been recognized by CDP, the world's foremost ...

From joint ventures to licensing deals, biotechnology is emerging as a strategic bridge between China and Japan.

Single-use technology manufacturing can attain cost-of-goods that are comparable to stainless-steel systems, noted WuXi.

CDMOs Expand Capabilities Amid Surge in Clinical Trials and Demand for Orphan Drugs and Novel TherapiesDublin, April 18, 2025 (GLOBE NEWSWI ...

The campaign marks the successful commercial-scale PPQ completion of Asia's first 3 X 5,000L single-use bioreactors ...

The Board of Directors of Adani Ports and Special Economic Zone Ltd. (APSEZ), India's largest integrated Transport Utility company has approved the acquisition of Abbot Point Port Holdings Pte Ltd ...

Amogy, a provider of mature, scalable, and efficient ammonia-to-power solutions, today announced the first pilot plant deployment of its advanced ammonia cracking catalyst with JGC Holdings ...

The trade relationship between the US and China has deteriorated significantly since President Trump's inauguration in January 2025. What began as a 10% additional tariff on Chinese goods in February ...

IntroductionThe Global Plasmid DNA Manufacturing Market is poised for significant growth, with a valuation of USD 2.13 ...

The global bioanalytical testing services market was worth USD 2.7 billion in 2020 and is further projected to reach USD 6.1 billion by 2027, at a CAGR of 12.1% during the forecast period (2021-2027).

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received five awards at the 2025 Asia-Pacific ...